<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>
<channel>
	<title>Comments on: Takeda Buys Millennium for $8.8 billion</title>
	<atom:link href="http://www.pharmababble.com/takeda-buys-millennium-for-88-billion/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmababble.com/takeda-buys-millennium-for-88-billion/</link>
	<description>Biomedical investment and business development chatter</description>
	<pubDate>Mon, 15 Mar 2010 03:26:02 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Alnylam and Takeda Form Alliance In RNAi &#124; Pharmababble</title>
		<link>http://www.pharmababble.com/takeda-buys-millennium-for-88-billion/comment-page-1/#comment-40</link>
		<dc:creator>Alnylam and Takeda Form Alliance In RNAi &#124; Pharmababble</dc:creator>
		<pubDate>Tue, 27 May 2008 13:25:56 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmababble.com/?p=17#comment-40</guid>
		<description>[...] deal at an interesting time for Takeda. They have been on a shopping spree recently (see: Millennium) tying to offset the coming generic competition of Prevacid and Actos and have not been shy about [...]</description>
		<content:encoded><![CDATA[<p>[...] deal at an interesting time for Takeda. They have been on a shopping spree recently (see: Millennium) tying to offset the coming generic competition of Prevacid and Actos and have not been shy about [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
